Curium inks definitive deal to acquire radiopharma rival Lantheus for up to $8B
“This combination unlocks an opportunity that neither company could achieve alone, as it positions us to reach significantly more patients and clinicians globally,” Curium CEO Renaud Dehareng said Aug. 3.